首页> 外文期刊>BMC Cardiovascular Disorders >The prognostic utility of GRACE risk score in predictive cardiovascular event rate in STEMI patients with successful fibrinolysis and delay intervention in non PCI-capable hospital: a retrospective cohort study
【24h】

The prognostic utility of GRACE risk score in predictive cardiovascular event rate in STEMI patients with successful fibrinolysis and delay intervention in non PCI-capable hospital: a retrospective cohort study

机译:回顾性队列研究:GRACE风险评分对STEMI患者成功行纤维蛋白溶解和延迟干预的STEMI患者的预测心血管事件发生率的预后效用:一项回顾性队列研究

获取原文
       

摘要

Background Fibrinolytic therapy is the main reperfusion therapy for most STEMI patients in several countries. Current practice guidelines recommended routine early pharmacoinvasive (within 3–24?h after successful fibrinolysis, however it cannot be performed in timely fashion due to limitation of PCI-capable hospitals. This study aimed to evaluate the prognostic utility of the GRACE score in patients receiving delayed intervention after successful fibrinolysis in non PCI-capable hospital. Methods We retrospectively analysed the data from the Maharaj Nakorn Chiang Mai Hospital acute ST-elevation myocardial infarction (STEMI) registry during the period 2007–2012. The STEMI patients who had successfully fibrionolysis in non PCI-capable hospital and received delayed PCI (during 24?h to 14?days after successful fibrinolytic therapy) at Maharaj Nakorn Chiang Mai hospital were included. The primary end point for this analysis was the composite outcomes, which included all-cause mortality, re-hospitalization with acute coronary syndrome (ACS), re-hospitalization with heart failure (HF) and stroke at 1 and 6-month. Results A total of 152 patients were included. 88 patients and 64 patients were in low GRACE group (GRACE risk score?≤?125) and intermediate to high GRACE group (GRACE risk score above 126), respectively. The median time from fibrinolysis to coronary intervention in low GRACE group was 8.5?days (interquartile range, 4.6–10.9) and 7.9?days (interquartile range,3.2,12.0) in intermediate to high GRACE group ( p =?0.482). At 1?month, the composite cardiovascular outcome at 1?month occurred in 2 patients (2.3?%) in low GRACE group and 10 patients (15.6?%) in intermediate to high GRACE group ( P =?0.003). During 6?months, the composite cardiovascular outcomes occurred in 6 patients (6.8?%) in low GRACE group and 12 patients (18.7?%) in intermediate to high GRACE group ( P =?0.024). The cumulative of composite cardiovascular outcome was significant higher in intermediate to high GRACE group than in low GRACE group (Hazard ratio: 2.97, 95?% CI 1.11–7.90; p =?0.030). Conclusion The long delay pharmacoinvasive strategy in intermediate to high GRACE score after successful fibrinolysis in non PCI-capable facilities were associated with worse cardiovascular outcomes than the patients with low GRACE score at 1 and 6?months. GRACE risk score may be helpful and guided the clinicians in non PCI-capable center in early transferred to early intervention in STEMI patients after fibrinolytic therapy.
机译:背景技术纤溶疗法是一些国家中大多数STEMI患者的主要再灌注疗法。当前的实践指南建议常规的早期药物侵入性治疗(成功的纤维蛋白溶解后3-24小时内,但是由于PCI能力有限的医院而不能及时进行。本研究旨在评估GRACE评分在接受患者治疗中的预后效用方法回顾性分析2007-2012年间Maharaj Nakorn Chiang Mai医院急性ST抬高心肌梗死(STEMI)登记册中的数据。包括在Maharaj Nakorn清迈医院没有PCI能力的医院和延迟接受PCI(成功的纤溶治疗后24小时至14天)的患者,该分析的主要终点是综合结果,其中包括全因死亡率,急性冠脉综合征(ACS)的再次住院,心力衰竭(HF)的再次住院和1岁时的中风和六个月。结果共纳入152例患者。低GRACE组(GRACE危险评分≤125)和中高危GRACE组(GRACE危险评分高于126)分别为88例和64例。在低至GRACE组中,从纤溶到冠状动脉介入治疗的中位时间为8.5?天(四分位间距为4.6-10.9)和中至高GRACE组的7.9?天(四分位间距为3.2、12.0)(p =?0.482)。在1个月时,低GRACE组的2例患者(2.3%)发生了1个月时的复合心血管预后,中高GRACE组的10例患者(15.6 %%)发生了(P = 0.003)。在6个月内,低GRACE组的6例患者(6.8%)发生了复合心血管结果,中高GRACE组的12例(18.7%)发生了心血管事件(P = 0.024)。中至高GRACE组的复合心血管预后的累积显着高于低GRACE组(危险比:2.97,95%CI 1.11–7.90; p =?0.030)。结论在没有PCI能力的设施中成功进行纤维蛋白溶解后,在GRACE评分中高至中的长期延迟药物治疗策略与1个月和6个月低GRACE评分的患者的心血管结局相关。 GRACE风险评分可能会有所帮助,并指导没有PCI能力的中心的临床医生在纤溶治疗后早期转移至STEMI患者的早期干预。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号